First-line nivolumab in stage IV or recurrent non-small-cell lung cancer

New England Journal of Medicine

Volumn 376, Issue 25, 2017, Pages 2415-2426

  Carbone, D P ^a   Reck, M ^b   Paz Ares, L ^d   Creelan, B ^g   Horn, L ^h   Steins, M ^c   Felip, E ^e   Van Den Heuvel, M M ^i,j   Ciuleanu, T E ^k   Badin, F ^l   Ready, N ^m   Hiltermann, T J N ⁱ   Nair, S ⁿ   Juergens, R ^q   Peters, S ^r   Minenza, E ^s   Wrangle, J M ^t   Rodriguez Abreu, D ^f   Borghaei, H ^o   Blumenschein, G R ^v   Villaruz, L C ^p   Havel, L ^v   Krejci, J ^v   Corral Jaime, J ^u   Chang, H ^w   Geese, W J ^w   Bhagavatheeswaran, P ^w   Chen, A C ^w   Socinski, M A ^p   more..

^a OHIO STATE UNIVERSITY   (United States)

^b GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^l Baptist Health Lexington   (United States)

^m DUKE UNIVERSITY   (United States)

ⁿ LEHIGH VALLEY HOSPITAL   (United States)

^o FOX CHASE CANCER CENTER   (United States)

^p UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^q JURAVINSKI CANCER CENTRE   (Canada)

^r LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^s S MARIA HOSPITAL   (Italy)

^t MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^u UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^v Nemocnice Na Bulovce   (Czech Republic)

^w BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; PLATINUM COMPLEX; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR IMMUNOGENICITY; VOMITING; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; LUNG TUMOR; METABOLISM;

ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS;

EID: 85020964772     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1613493     Document Type: Article

References (20)

1. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Canc Netw 2016; 14:255-64.
2. Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2015; 33: 3488-515.
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
4. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as firstline therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30: 2055-62.
5. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31:4349-57.
6. Paz-Ares L, Mezger J, Ciuleanu TE, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 2015; 16:328-37.
7. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16:763-74.
8. Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 2015; 10: 134-42.
9. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35.
10. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39.
11. Barlesi F, Steins M, Horn L, et al. Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update. Ann Oncol 2016; 27:Suppl 6:215PD. abstract.
12. Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016; 34: 2980-7.
13. Gettinger S, Shepherd FA, Antonia SJ, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, June 3-7, 2014 (poster).
14. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
16. Wakelee HA, Wang W, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 2006; 1: 441-6.
17. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33.
18. Remon J, Besse B, Soria JC. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med 2017; 15:55.
19. Hellmann M. Mutation burden, neo-antigens, and response to T cell checkpoint blockade. Presented at the 14th International Congress on Targeted Anticancer Therapies, Washington, DC, March 21-23, 2016.
20. Kowanetz M, Zou W, Shames D, et al. Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients. J Thorac Oncol 2017; 12: Suppl: S321. abstract.